Management of Severe Hypertension Without Acute Organ Damage

Definitions

• Hypertensive urgency is defined as a systolic/diastolic blood pressure ≥ 180/110 mmHg without evidence of acute target‑organ damage (e.g., heart failure, stroke, renal injury). – American Heart Association/American College of Cardiology, Class III: Harm recommendation. 1, 2
• Hypertensive emergency requires blood pressure > 180/120 mmHg plus acute target‑organ damage such as pulmonary edema, encephalopathy, myocardial ischemia, stroke, or advanced retinopathy. – American Heart Association/American College of Cardiology. 1, 2

What NOT to Do (Class III: Harm)

• Do not administer intermittent intravenous antihypertensive agents (including IV nicardipine) to patients with severe hypertension who lack acute organ damage. – AHA/ACC, Class III: Harm. 1, 2
• Do not give additional oral antihypertensive medications with the intent of acutely lowering blood pressure in this setting. – AHA/ACC, Class III: Harm. 1, 2
• Avoid hospital admission solely for hypertensive urgency when no other indication exists. – AHA/ACC, Class III. 1, 2

Risks of Aggressive Acute Lowering

• Rapid reduction of blood pressure in patients with chronic hypertension can precipitate vital‑organ hypoperfusion because autoregulatory mechanisms are impaired. – AHA/ACC. 1, 2

Recommended Outpatient Management

• Re‑initiate or intensify long‑acting oral antihypertensive therapy in the outpatient or ambulatory setting, using agents with extended half‑lives. – AHA/ACC. 1, 2
• Arrange close outpatient follow‑up to monitor blood pressure trends and address the elevated cardiovascular risk. – AHA/ACC. 1, 2

Outcomes and Evidence

• Patients presenting with hypertensive urgency have a 20–30 % one‑year cardiovascular morbidity and mortality rate; this risk is not reduced by acute intravenous therapy. – AHA/ACC. 1, 2
• No randomized controlled trial evidence demonstrates that acute antihypertensive drug administration lowers morbidity or mortality in hypertensive urgency. – AHA/ACC. 1, 2

Appropriate Use of IV Nicardipine

• IV nicardipine is reserved for true hypertensive emergencies (BP > 180/120 mmHg with acute organ damage requiring ICU care). – AHA/ACC. 1, 2
• In a hypertensive emergency, systolic blood pressure should be reduced by no more than 25 % within the first hour, then to < 160/100 mmHg over the subsequent 2–6 hours. – AHA/ACC. 1, 2

Practical Algorithm

• Step 1 – Verify measurement: Obtain multiple, properly performed blood pressure readings (correct cuff size, patient seated, rest period). – AHA/ACC. 1, 2

• Step 2 – Screen for organ damage: Assess for chest pain, dyspnea, neurologic deficits, acute renal failure, or advanced retinopathy. – AHA/ACC. 1, 2

  If *no* organ damage is identified:

  • Do not give IV or acute oral antihypertensives. – AHA/ACC. 1, 2
  • Restart or uptitrate the patient’s existing oral antihypertensive regimen. – AHA/ACC. 1, 2
  • Discharge with scheduled close outpatient follow‑up. – AHA/ACC. 1, 2

  If *organ damage* is present:

  • Admit to an intensive‑care unit. – AHA/ACC. 1, 2
  • Initiate continuous IV nicardipine (or another parenteral agent) with dosing titrated to achieve the recommended BP reduction targets. – AHA/ACC. 1, 2
  • Continuously monitor blood pressure and organ‑function parameters. – AHA/ACC. 1, 2

Management of Hypertensive Urgency in Adults

Diagnostic Distinction

• In adults presenting with blood pressure ≥ 180/110 mmHg without acute target‑organ damage, the condition is classified as hypertensive urgency; the presence of any acute organ injury (e.g., myocardial ischemia, pulmonary edema, acute renal failure, encephalopathy, stroke, or advanced retinopathy) reclassifies it as a hypertensive emergency requiring immediate intravenous therapy and intensive‑care monitoring. 3

Outpatient Management Strategy – What to Do

• Re‑initiate or intensify long‑acting oral antihypertensive agents (chosen according to the patient’s current regimen, comorbidities, and reasons for the blood‑pressure rise) and aim for a gradual reduction of at least 20 % of the baseline BP over the next 24–48 hours. This approach is performed in the outpatient/ambulatory setting; hospitalization is not required unless other non‑hypertensive indications exist. 3
• Arrange close outpatient follow‑up to ensure sustained blood‑pressure control and to address the higher cardiovascular risk associated with hypertensive urgency. 3

Outpatient Management Strategy – What NOT to Do

• Do not administer intermittent intravenous antihypertensive medications for hypertensive urgency. 3
• Do not hospitalize patients solely for hypertensive urgency unless there are additional, non‑hypertensive reasons for admission. 3

Guideline Recommendation (2025 AHA/ACC)

• The 2025 American Heart Association/American College of Cardiology (AHA/ACC) guideline issues a Class III: Harm recommendation (Level B‑NR) against the use of additional IV or oral antihypertensive drugs to acutely lower blood pressure in hospitalized patients with severe hypertension (> 180/120 mmHg) when no acute target‑organ damage is present. 3

Medication Selection

• Prefer long‑acting oral agents with extended half‑lives over short‑acting formulations; selection should be individualized based on the patient’s existing antihypertensive therapy, comorbid conditions, and identified precipitants of the BP elevation. 3

Confirmation of Blood‑Pressure Elevation

• Verify elevated blood pressure with multiple, properly performed measurements (appropriate cuff size, correct patient positioning, and a resting period) before initiating any therapeutic changes. 3

Hypertensive Urgency: Definition and Diagnostic Criteria

Definition

• Hypertensive urgency is defined by a severely elevated blood pressure (≥ 180/110 mmHg) without acute hypertension‑mediated organ damage. 4

Blood Pressure Threshold (Guideline Recommendation)

• Current European cardiovascular guidelines set the diagnostic threshold for hypertensive urgency at systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg. 5

Distinguishing Features – Absence of Acute Organ Damage

• The principal clinical distinction between hypertensive urgency and hypertensive emergency is the absence of acute organ damage (no retinal, neurological, cardiac, pulmonary, or renal involvement). 6
• Patients with hypertensive urgency do not exhibit advanced retinopathy such as flame hemorrhages, cotton‑wool spots, or papilledema. 7
• Acute chest pain suggestive of myocardial ischemia is not present in hypertensive urgency. 5
• Acute dyspnea resulting from pulmonary edema is absent in hypertensive urgency. 5
• Acute renal failure is not observed in hypertensive urgency. 7

Hypertensive Urgency vs. Emergency: ESC‑Guided Criteria

Blood‑Pressure Thresholds

• The European Society of Cardiology (ESC) guideline (2019) adopts a systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg as the threshold for defining hypertensive urgency when no acute organ injury is present. 8
• The ESC guideline (2019) characterises malignant hypertension (a form of hypertensive emergency) as usually exceeding 200/120 mmHg together with advanced retinal damage. 8

Acute Target‑Organ Damage Defining Hypertensive Emergency

Neurologic Manifestations

• Hypertensive encephalopathy presenting with seizures, altered consciousness, cortical visual loss, or coma is a hallmark of emergency hypertension. 8
• Acute ischemic or hemorrhagic stroke is listed as an emergency‑level manifestation. 8

Cardiac Manifestations

• Acute coronary syndrome (myocardial infarction or unstable angina) signifies a hypertensive emergency. 8
• Acute cardiogenic pulmonary edema is identified as an emergency presentation. 8

Vascular Manifestations

• Acute aortic dissection or rapidly expanding aneurysm constitutes emergency hypertension. 8

Renal Manifestations

• Acute renal failure is recognized as a target‑organ injury in hypertensive emergency. 8
• Thrombotic microangiopathy (microangiopathic hemolysis with thrombocytopenia) is also included as an emergency criterion. 8

Ophthalmologic Manifestations

• Advanced retinopathy with bilateral flame‑shaped hemorrhages, cotton‑wool spots, or papilledema defines emergency hypertension. 8

Obstetric Manifestations

• Severe pre‑eclampsia, eclampsia, or HELLP syndrome are classified as hypertensive emergencies in pregnant patients. 8

Diagnostic Pitfalls Highlighted by ESC

• The ESC (2019) stresses that hypertensive urgency is a diagnosis of exclusion; clinicians must actively search for any organ injury rather than assume its absence based solely on blood‑pressure values. 8
• Up to one‑third of patients with hypertensive encephalopathy may lack overt retinal changes, underscoring the need for neuro‑imaging when neurologic symptoms are present. 8

Outcomes and Management Implications

• According to the ESC (2019), patients classified with hypertensive urgency experience a 20–30 % rate of cardiovascular morbidity and mortality within one year; this risk is not mitigated by acute intravenous antihypertensive therapy but is reduced through sustained long‑term blood‑pressure control. 8

Hypertensive Urgency: Evidence‑Based Identification and Pharmacologic Management

Definition and Acute‑Organ‑Damage Screening

• In adults presenting with severe hypertension (e.g., BP ≈ 180/120 mmHg) who lack acute target‑organ damage—such as neurologic events (seizures, altered consciousness, stroke symptoms), cardiac events (chest pain, pulmonary edema), renal impairment (acute failure, oliguria), ophthalmologic findings (flame hemorrhages, papilledema), or vascular emergencies (aortic dissection)—the condition is classified as hypertensive urgency rather than hypertensive emergency. 9

Pharmacologic Management Recommendations

• Avoid short‑acting antihypertensive agents (e.g., immediate‑release nifedipine) because rapid BP reductions can precipitate cardiovascular complications and organ hypoperfusion. 9
• Preferred oral medication classes for intensifying therapy in hypertensive urgency are:
  
  • Thiazide or thiazide‑like diuretics,
  • Angiotensin‑converting‑enzyme inhibitors (ACE‑I) or angiotensin‑receptor blockers (ARB),
  • Long‑acting calcium‑channel blockers (e.g., amlodipine).

Long‑Term Blood‑Pressure Targets

• After the acute phase, the treatment goal for all adult patients is to achieve and maintain a blood pressure < 130/80 mmHg, consistent with the 2025 AHA/ACC recommendations. 10

Communication and Follow‑Up (Guideline‑Concordant Care)

• Pharmacist‑physician collaborative management that follows the 2025 AHA/ACC guideline is recommended for patients with hypertensive urgency, ensuring appropriate medication adjustments and timely outpatient follow‑up. 10